AstraZeneca's lung cancer drug datopotamab deruxtecan, also called Dato-DXd, failed to show a significant benefit to overall survival when compared to standard chemotherapy drug docetaxel, according to trial results published Sept. 9 in the Journal of Clinical Oncology.
Researchers treating patients with advanced/metastatic non–small cell lung cancer participated in the TROPION-Lung01 global phase III study. Of the participants, 299 received Dato-DXd and 305 received docetaxel.
In the overall trial population, Dato-DXd increased overall survival by 1.1 months. For patients with nonsquamous histology, survival increased by 2.3 months.
For patients with nonsquamous histology and actionable genomic alterations, Dato-DXd increased survival by 5.8 months. For patients with nonsquamous histology and no actionable genomic alterations, Dato-DXd increased survival by 1.3 months.
While the results showed a numerical benefit, they also showed Dato-DXd had no statistically significant effect on overall survival, the study authors wrote.